A phase 1b Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF).
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Samus Therapeutics, Inc.
Start Date
July 10, 2018
End Date
October 22, 2021
Administered By
Duke Cancer Institute
Awarded By
Samus Therapeutics, Inc.
Start Date
July 10, 2018
End Date
October 22, 2021